142 related articles for article (PubMed ID: 15839918)
1. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.
Gårdmark T; Wester K; De la Torre M; Carlsson J; Malmström PU
BJU Int; 2005 May; 95(7):982-6. PubMed ID: 15839918
[TBL] [Abstract][Full Text] [Related]
2. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.
Wei Q; Chen L; Sheng L; Nordgren H; Wester K; Carlsson J
Int J Oncol; 2007 Sep; 31(3):493-9. PubMed ID: 17671674
[TBL] [Abstract][Full Text] [Related]
3. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
4. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER2/neu in primary and metastatic breast cancer.
Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
[TBL] [Abstract][Full Text] [Related]
6. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
7. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy.
Shang J; Shui Y; Sheng L; Wang K; Hu Q; Wei Q
Oncol Rep; 2008 Feb; 19(2):435-40. PubMed ID: 18202792
[TBL] [Abstract][Full Text] [Related]
9. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
10. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder.
Hauser-Kronberger C; Peham K; Grall J; Rausch W; Hutarew G; Dietze O
J Urol; 2006 Mar; 175(3 Pt 1):875-80; discussion 880. PubMed ID: 16469569
[TBL] [Abstract][Full Text] [Related]
11. EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy.
Wei Q; Shui Y; Zheng S; Wester K; Nordgren H; Nygren P; Glimelius B; Carlsson J
Oncol Rep; 2011 Jan; 25(1):3-11. PubMed ID: 21109951
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study.
Masood S; Bui MM
Ann Clin Lab Sci; 2000 Jul; 30(3):259-65. PubMed ID: 10945565
[TBL] [Abstract][Full Text] [Related]
13. HER2 gene status in primary breast cancers and matched distant metastases.
Tapia C; Savic S; Wagner U; Schönegg R; Novotny H; Grilli B; Herzog M; Barascud AD; Zlobec I; Cathomas G; Terracciano L; Feichter G; Bubendorf L
Breast Cancer Res; 2007; 9(3):R31. PubMed ID: 17511881
[TBL] [Abstract][Full Text] [Related]
14. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.
Wei Q; Sheng L; Shui Y; Hu Q; Nordgren H; Carlsson J
Ann Surg Oncol; 2008 Apr; 15(4):1193-201. PubMed ID: 18172732
[TBL] [Abstract][Full Text] [Related]
15. Expression of the epidermal growth factor receptor family in normal and malignant urothelium.
Røtterud R; Nesland JM; Berner A; Fosså SD
BJU Int; 2005 Jun; 95(9):1344-50. PubMed ID: 15892828
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
Hofmann M; Stoss O; Shi D; Büttner R; van de Vijver M; Kim W; Ochiai A; Rüschoff J; Henkel T
Histopathology; 2008 Jun; 52(7):797-805. PubMed ID: 18422971
[TBL] [Abstract][Full Text] [Related]
17. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.
Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Takata D; Rokutanda N; Nagaoka R; Oyama T; Iino Y; Morishita Y
Oncol Rep; 2005 Nov; 14(5):1109-16. PubMed ID: 16211272
[TBL] [Abstract][Full Text] [Related]
18. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R; Stevens J; McKinney C; Ibrahim NB
Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]